If the only detectable mutations are in the DTA genes, it is recommended to use MFC and/or PCR for the MRD assessment; mutations in signaling pathway genes (e.g., FLT3-ITD, FLT3-TKD, KIT, KRAS, and NRAS) likely represent residual AML when detected, but they are often subclonal and have a low negative predictive value. Here, FLT3 is linked to acute myeloid leukemia.